Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy.

Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Abstract Text:

    bjoern hoffmannBjoern Hoffmann,martin schwarzMartin Schwarz,atul mehtaAtul Mehta,satish keshavSatish Keshav, ,bjoern hoffmannBjoern Hoffmann,martin schwarzMartin Schwarz,atul mehtaAtul Mehta,satish keshavSatish Keshav, ,

    BACKGROUND & AIMS: Fabry disease is an X-linked deficiency of alpha-galactosidase A, resulting in lysosomal deposition of globotriaosylceramide in nearly all tissues. The disease frequently causes diarrhea and abdominal pain, which are assumed to arise from malfunction of enteric neurons and which mimic diarrhea-predominant irritable bowel syndrome (IBS). There are limited data about the prevalence and nature of gastrointestinal symptoms in patients with Fabry disease and the response to enzyme replacement therapy (ERT) in large cohorts. The aims of this study were to evaluate the nature and prevalence of gastrointestinal symptoms and their impact on health-related quality of life (HRQoL) in patients with Fabry disease and to analyze changes after 12 and 24 months of treatment with agalsidase alfa. METHODS: Information about gastrointestinal symptoms was obtained from regular interviews before and during the time of ERT. Data on HRQoL were collected by using the EQ-5D questionnaire. RESULTS: The overall prevalence of gastrointestinal symptoms was 52%, with abdominal pain and diarrhea being most frequent. Female patients were more frequently affected than male patients, and there was a high prevalence in children (abdominal pain, 49.3%; diarrhea 25.4%). ERT with agalsidase alfa reduced the prevalence of abdominal pain, with a statistically significant decrease in male patients and in children after 12 months of treatment. CONCLUSIONS: The gastrointestinal symptomatology of Fabry disease is very similar to diarrhea-predominant IBS; however, pathophysiologic similarities remain to be elucidated. ERT reduced the prevalence of gastrointestinal symptoms in Fabry disease, particularly in children and male patients.

    Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Publishing Authors By Initials

    b hoffmannB Hoffmann,m schwarzM Schwarz,a mehtaA Mehta,s keshavS Keshav, ,b hoffmannB Hoffmann,m schwarzM Schwarz,a mehtaA Mehta,s keshavS Keshav, ,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Journal Published:

    PUBLICATION TYPE: Research Support, Non-U.S. Gov

    Journal: Clinical gastroenterology and hepatology : the off

    VOLUME: 5

    Page Numbers: 1447-53

    Journal Abbreviation: Clin. Gastroenterol. Hepatol.

    ISSN: 1542-7714

    DAY: 24

    MONTH: 10

    YEAR: 2007

    Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 101160775

    Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy.

    AFFILIATION: Department of General Pediatrics, University Children's Hospital, Heinrich-Heine-University, Duesseldorf, Germany.

    Country: United States

    United States Research PublicationUnited States Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Clin Gastroenterol Hepatol

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News